About JumpCode Genomics
JumpCode Genomics is a private company based in San Diego, California. It has reported $38,672,598 raised in five offerings on Form D since September 2018. Its chief executive is David Salter.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Aug 22, 2024 | $3,458,827of $11.4M target | 8 | $432K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 27, 2023 | May 9, 2023 | $9,189,499of $16.1M target | 7 | $1.3M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 18, 2020 | Dec 26, 2020 | $21,012,997fully sold | 5 | $4.2M | EquityRule 506(b) | Form D ↗ |
| Jan 27, 2020 | Feb 11, 2020 | $1,500,000fully sold | 1 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Sep 4, 2018 | Sep 12, 2018 | $3,511,275fully sold | 4 | $877K | EquityRule 506(b) | Form D ↗ |
| Total, five offerings | $38,672,598 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on JumpCode Genomics's Form D filed Aug 22, 2024.
Earlier filings also listed Yaron Hakak (chief executive officer and director, last listed May 2023), Kirk Malloy (director, last listed May 2023), Frank Witney (director, last listed May 2023), Dan Kidle (director, last listed May 2023), Brandon Poe (executive officer, last listed May 2023), Michael Liang (director, last listed Dec 2020), Kevin Li (director, last listed Dec 2020) and Keith Brown (executive officer, last listed Dec 2020).